XML 61 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2025
Disclosure of operating segments [abstract]  
Schedule of Segment Results
Segment results are shown in the table below:
June 30, 2025 (6 months)
(€ million)Biopharma
Other
Total
June 30, 2025
Change vs. June 30, 2024 on a reported basis (IFRS)
Change vs. June 30, 2024 at constant exchange rates (non-IFRS)
June 30, 2025
Change vs. June 30, 2024 on a reported basis (IFRS)
Change vs. June 30, 2024 at constant exchange rates (non-IFRS)
June 30, 2025
Change vs. June 30, 2024 on a reported basis (IFRS)
Change vs. June 30, 2024 at constant exchange rates (non-IFRS)
Net sales19,889 +8.3%+9.9%— %19,889 +8.3%+9.9%
Other revenues1,246 -7.8%-6.4%206 +16.4%+15.3%1,452 -5.0%-3.9%
Cost of sales(5,753)-1.6%-0.1%(128)+16.4%+14.5%(5,881)-1.3%+0.2%
Research and development expenses(3,716)+11.5%+12.3%(1)—%—%(3,717)+11.5%+12.3%
Selling and general expenses(4,447)+4.7%+5.9%(59)+5.4%+5.4%(4,506)+4.7%+5.9%
Other operating income and expenses(1,941)(2)(1,943)
Share of profit/(loss) from investments accounted for using the equity method77 — 77 
Net income attributable to non-controlling interests(8)— (8)
Business operating income5,347 +8.8%+11.0%16 -27.3%-27.3%5,363 +8.6%+10.8%
      As % of net sales
26.9%27.0%

June 30, 2024 (6 months) (a)
(€ million)Biopharma
Other
Total
Net sales18,360 18,360 
Other revenues1,352 177 1,529 
Cost of sales(5,849)(110)(5,959)
Research and development expenses(3,334)(1)(3,335)
Selling and general expenses(4,247)(56)(4,303)
Other operating income and expenses(1,426)12 (1,414)
Share of profit/(loss) from investments accounted for using the equity method66 — 66 
Net income attributable to non-controlling interests(6)— (6)
Business operating income4,916 22 4,938 
(a)Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method
The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method:
(€ million)June 30, 2025 (6 months)June 30, 2024 (6 months) (a)
Business operating income5,363 4,938 
Share of profit/(loss) from investments accounted for using the equity method(b)
(77)(66)
Net income attributable to non-controlling interests(c)
8 6 
Amortization and impairment of intangible assets(d)
(987)(527)
Fair value remeasurement of contingent consideration(61)(66)
Expense arising from the impact of acquisitions on inventories(e)
— (7)
Restructuring costs and similar items(f)
(430)(1,060)
Other gains and losses, and litigation(g)
(57)(450)
Operating income3,759 2,768 
Financial expenses(361)(583)
Financial income184 277 
Income before tax and investments accounted for using the equity method3,582 2,462 
(a)Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
(b)Joint ventures and associates with which Sanofi has entered into a strategic alliance.
(c)Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.
(d)The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €210 million in the first half of 2025 linked to research and development projects. .As of June 30, 2024, this line includes a net reversal of impairment losses amounting to €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights.
(e)This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.
(f)See Note B.16.
(g)See Note B.17.
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment
Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.

Biopharma
(€ million)June 30, 2025June 30, 2024
Investments accounted for using the equity method (a)
483 229 
Acquisitions of property, plant and equipment845 882 
Acquisitions of other intangible assets575 922 
(a)    Carrying amount at the end of the reporting period.
Summary of Geographical Information on Net Sales and Non-Current Assets
In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.
(€ million)June 30, 2025December 31, 2024
Property, plant and equipment
Goodwill
Other intangible assets
Property, plant and equipment
Goodwill
Other intangible assets
Europe
5,438 — 3,167 5,550 — 3,307 
of which France
2,953 — — 3,112 — — 
United States2,080 — 16,725 2,411 — 18,711 
Rest of the World
2,056 — 539 2,130 — 611 
of which China
83 — — 96 — — 
Total
9,574 40,283 20,431 10,091 43,384 22,629